Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Aug;28(4):343-62.
doi: 10.1023/a:1011582713692.

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance

Affiliations

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance

J Lu et al. J Pharmacokinet Pharmacodyn. 2001 Aug.

Abstract

For single-dose concentration-time data collected in clinical trials to be useful for explanatory pharmacokinetic (PK) or pharmacokinetic-pharmacodynamic (PK-PD) analyses, the following two assumptions on the data must hold: (i) the times of the concentration (PK) observations are known, and (ii) the patient's recent past dosing history (times and amounts) is known. If either (or both) of these assumptions does not hold, and data analysis proceeds as if it did, biased estimates may result. Assumption (i) usually does hold as study personnel observe and record PK sampling times. Assumption (ii) is a problem when, as is often the case of outpatient studies, one must rely on patient recall for past dosing history. This paper presents a technique to avoid assumption (ii) by identifying for deletion those PK observation occasions likely exhibiting unreliable preceding dose histories. To so identify occasions, a Bayes objective function (posterior density) for the data is maximized in its parameters for each individual. The likelihood factor of this function is a mixture pharmacostatistical model expressing the likelihood of the observed concentration(s) under three mutually exclusive events: the prescribed dose preceding the occasion was not taken at all (NT), the prescribed dose was taken at the specified time (T), or the prescribed dose was taken at an unspecified time (U). Suspect observations are identified as those whose maximum corresponding likelihood component is other than T. The approach as defined here relies on the following assumptions in addition to (i): (ii) population PK (i.e., the distribution of PK parameters in the population being sampled) is known, at least approximately. (iii) PK samples (at least 1 or 2 per occasion) are available, (iv) doses taken are of the stated magnitude, and (v) the drug has a short half-life. Simulations reveal that especially when more than one PK sample is available per study occasion, the methodology chooses a set of PK observations that should perform better in subsequent explanatory analyses, or as a basis for estimating individual PK parameters, than do other simpler methods.

PubMed Disclaimer

References

    1. J Pharm Sci. 1982 Dec;71(12):1344-8 - PubMed
    1. J Infect Dis. 1995 Mar;171 Suppl 2:S99-112 - PubMed
    1. Clin Pharmacokinet. 1994 Sep;27(3):202-15 - PubMed
    1. N Engl J Med. 1996 Oct 10;335(15):1081-90 - PubMed
    1. Stat Med. 1998 Feb 15;17(3):341-55 - PubMed

Publication types